Purdue Pharma Canada

6 articles about Purdue Pharma Canada

• AKYNZEO® Oral now covered by the Ontario, Quebec and Non-Insured Health Benefits public drugs plans

  7/10/2019

  Purdue Pharma is pleased to announce that AKYNZEO® Oral is now reimbursed by the Ontario Public Drug Program and the Régie de l'assurance maladie du Québec and by the Non-Insured Health Benefits program for the prevention of chemotherapy induced nausea and vomiting.

• FOQUEST® Receives Approval for Expanded Indication for Children and Adolescents with ADHD

  3/12/2019

  First and only methylphenidate product approved in Canada that provides control of ADHD symptoms throughout the day

• Klaria Signs Exclusive Development, License And Supply Agreement With Purdue Pharma Canada For Acute Treatment Of Opioid Overdose (KL-00514)

  8/9/2017

• Helsinn Group Signs Exclusive Agreement With Purdue Pharma Canada For The Distribution And Licensing Rights Of Akynzeo (Netupitant/Palonosetron Combo) In Canada

  4/25/2016

• Ontario Government Investment Supports R&D Expansion at Purdue Pharma Canada ; Sites 53 New Jobs

  12/5/2008

• Purdue Pharma L.P. (Connecticut) Chooses Edge Dynamics To Manage Channel Agreements And Optimize Channel Commerce

  12/12/2005